Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
UCLA researchers, in an animal study published in the Aug. 1 issue of the journal Clinical Cancer Research, have found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
- UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
UCLA researchers, in an animal study published in the Aug. 1 issue of the journal Clinical Cancer Research, have found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
- UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
UCLA researchers, in an animal study published in the Aug. 1 issue of the journal Clinical Cancer Research, have found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
- UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
UCLA researchers, in an animal study published in the Aug. 1 issue of the journal Clinical Cancer Research, have found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
- GliSODin study on oxidative stress in immune compromised humans included in the 2006 XVI International AIDS Conference
A study on Glisodin and immune compromised individuals at the AIDS 2006 - XVI International AIDS Conference, August 13-18 2006, held in Toronto. In the study, Glisodin was shown to restore the circulating antioxidant capacities, including Superoxide Dismustase (SOD), in the Glisodin group, compared to no change in the control and placebo group.
- GliSODin study on oxidative stress in immune compromised humans included in the 2006 XVI International AIDS Conference
A study on Glisodin and immune compromised individuals at the AIDS 2006 - XVI International AIDS Conference, August 13-18 2006, held in Toronto. In the study, Glisodin was shown to restore the circulating antioxidant capacities, including Superoxide Dismustase (SOD), in the Glisodin group, compared to no change in the control and placebo group.
- GliSODin study on oxidative stress in immune compromised humans included in the 2006 XVI International AIDS Conference
A study on Glisodin and immune compromised individuals at the AIDS 2006 - XVI International AIDS Conference, August 13-18 2006, held in Toronto. In the study, Glisodin was shown to restore the circulating antioxidant capacities, including Superoxide Dismustase (SOD), in the Glisodin group, compared to no change in the control and placebo group.
- GliSODin study on oxidative stress in immune compromised humans included in the 2006 XVI International AIDS Conference
A study on Glisodin and immune compromised individuals at the AIDS 2006 - XVI International AIDS Conference, August 13-18 2006, held in Toronto. In the study, Glisodin was shown to restore the circulating antioxidant capacities, including Superoxide Dismustase (SOD), in the Glisodin group, compared to no change in the control and placebo group.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Study Indicates GliSODin® Shown to Inhibit Surgery-Related Cellular DNA Damage
P.L. Thomas, in association with Isocell, Paris, France, announced the results of a new study, indicating that GliSODin, supplementation prior to an invasive surgical procedure, was shown to significantly inhibit several measures of cellular damage, including DNA damage and protection of spinal cord tissues, without negative effects or impairing organ function.
- Study Indicates GliSODin® Shown to Inhibit Surgery-Related Cellular DNA Damage
P.L. Thomas, in association with Isocell, Paris, France, announced the results of a new study, indicating that GliSODin, supplementation prior to an invasive surgical procedure, was shown to significantly inhibit several measures of cellular damage, including DNA damage and protection of spinal cord tissues, without negative effects or impairing organ function.
- Study Indicates GliSODin® Shown to Inhibit Surgery-Related Cellular DNA Damage
P.L. Thomas, in association with Isocell, Paris, France, announced the results of a new study, indicating that GliSODin, supplementation prior to an invasive surgical procedure, was shown to significantly inhibit several measures of cellular damage, including DNA damage and protection of spinal cord tissues, without negative effects or impairing organ function.
- Study Indicates GliSODin® Shown to Inhibit Surgery-Related Cellular DNA Damage
P.L. Thomas, in association with Isocell, Paris, France, announced the results of a new study, indicating that GliSODin, supplementation prior to an invasive surgical procedure, was shown to significantly inhibit several measures of cellular damage, including DNA damage and protection of spinal cord tissues, without negative effects or impairing organ function.
- Study Indicates GliSODin® Shown to Inhibit Surgery-Related Cellular DNA Damage
P.L. Thomas, in association with Isocell, Paris, France, announced the results of a new study, indicating that GliSODin, supplementation prior to an invasive surgical procedure, was shown to significantly inhibit several measures of cellular damage, including DNA damage and protection of spinal cord tissues, without negative effects or impairing organ function.
- Harvard Men’s Health Watch: Red wine protects the prostate
Researchers in Seattle collected information about many factors that might influence the risk of prostate cancer in men between ages 40 and 64, including alcohol consumption, determining that men who drink an average of four to seven glasses of red wine per week are only 52% as likely to be diagnosed with prostate cancer as those who do not drink red wine.
- Harvard Men’s Health Watch: Red wine protects the prostate
Researchers in Seattle collected information about many factors that might influence the risk of prostate cancer in men between ages 40 and 64, including alcohol consumption, determining that men who drink an average of four to seven glasses of red wine per week are only 52% as likely to be diagnosed with prostate cancer as those who do not drink red wine.
- Harvard Men’s Health Watch: Red wine protects the prostate
Researchers in Seattle collected information about many factors that might influence the risk of prostate cancer in men between ages 40 and 64, including alcohol consumption, determining that men who drink an average of four to seven glasses of red wine per week are only 52% as likely to be diagnosed with prostate cancer as those who do not drink red wine.
- Harvard Men’s Health Watch: Red wine protects the prostate
Researchers in Seattle collected information about many factors that might influence the risk of prostate cancer in men between ages 40 and 64, including alcohol consumption, determining that men who drink an average of four to seven glasses of red wine per week are only 52% as likely to be diagnosed with prostate cancer as those who do not drink red wine.
- Study Provides Evidence That Maitake D-Fraction® to be Effective Against Bladder Cancer Cells
A study recently published in the Alternative Medicine Review magazine (vol. 12, Number 1, 2007) presented evidence of the superior cancer-inhibiting activity of Grifron®-Pro Maitake D-Fraction® (GD) on human bladder cancer cells over other natural anti-cancer products.
- Study Provides Evidence That Maitake D-Fraction® to be Effective Against Bladder Cancer Cells
A study recently published in the Alternative Medicine Review magazine (vol. 12, Number 1, 2007) presented evidence of the superior cancer-inhibiting activity of Grifron®-Pro Maitake D-Fraction® (GD) on human bladder cancer cells over other natural anti-cancer products.
- Study Provides Evidence That Maitake D-Fraction® to be Effective Against Bladder Cancer Cells
A study recently published in the Alternative Medicine Review magazine (vol. 12, Number 1, 2007) presented evidence of the superior cancer-inhibiting activity of Grifron®-Pro Maitake D-Fraction® (GD) on human bladder cancer cells over other natural anti-cancer products.
- A diet rich in omega-3 fatty acids may lower prostate cancer genetic risk
Researchers observe that, based on amouse model study, a diet rich in omega-3 polyunsaturated fatty acids found in certain fish or fish oil, nuts, seeds, and vegetable oils may help lower prostate cancer risk in individuals with a genetic predisposition to cancer.
- A diet rich in omega-3 fatty acids may lower prostate cancer genetic risk
Researchers observe that, based on amouse model study, a diet rich in omega-3 polyunsaturated fatty acids found in certain fish or fish oil, nuts, seeds, and vegetable oils may help lower prostate cancer risk in individuals with a genetic predisposition to cancer.
- A diet rich in omega-3 fatty acids may lower prostate cancer genetic risk
Researchers observe that, based on amouse model study, a diet rich in omega-3 polyunsaturated fatty acids found in certain fish or fish oil, nuts, seeds, and vegetable oils may help lower prostate cancer risk in individuals with a genetic predisposition to cancer.
- A diet rich in omega-3 fatty acids may lower prostate cancer genetic risk
Researchers observe that, based on amouse model study, a diet rich in omega-3 polyunsaturated fatty acids found in certain fish or fish oil, nuts, seeds, and vegetable oils may help lower prostate cancer risk in individuals with a genetic predisposition to cancer.
- Green tea may halve risk of colon cancer
A study from China, published in Cancer Epidemiology, Biomarkers and Prevention, has reported beneficial associations between regular consumption of green tea and colorectal cancer risk.
- Green tea may halve risk of colon cancer
A study from China, published in Cancer Epidemiology, Biomarkers and Prevention, has reported beneficial associations between regular consumption of green tea and colorectal cancer risk.
- Green tea may halve risk of colon cancer
A study from China, published in Cancer Epidemiology, Biomarkers and Prevention, has reported beneficial associations between regular consumption of green tea and colorectal cancer risk.
- Cargill announces positive results of clinical study using Cosucra's prebiotic inulin
A double-blind, randomized, placebo-controlled study, published in the journal Nutrition Research, has found that after four weeks of consuming 2.5 grams of inulin twice daily, there was a 10-fold increase in counts of beneficial Bifidobacteria among healthy volunteers. According to a releasze issued by Cargill, which distributes the prebiotic inulin used in the study, those consuming inulin also experienced a noted decrease in activity of beta-glucuronidase, an enzyme that may play a role in increasing the amount of carcinogens in the colon.
- Cargill announces positive results of clinical study using Cosucra's prebiotic inulin
A double-blind, randomized, placebo-controlled study, published in the journal Nutrition Research, has found that after four weeks of consuming 2.5 grams of inulin twice daily, there was a 10-fold increase in counts of beneficial Bifidobacteria among healthy volunteers. According to a releasze issued by Cargill, which distributes the prebiotic inulin used in the study, those consuming inulin also experienced a noted decrease in activity of beta-glucuronidase, an enzyme that may play a role in increasing the amount of carcinogens in the colon.
- Cargill announces positive results of clinical study using Cosucra's prebiotic inulin
A double-blind, randomized, placebo-controlled study, published in the journal Nutrition Research, has found that after four weeks of consuming 2.5 grams of inulin twice daily, there was a 10-fold increase in counts of beneficial Bifidobacteria among healthy volunteers. According to a releasze issued by Cargill, which distributes the prebiotic inulin used in the study, those consuming inulin also experienced a noted decrease in activity of beta-glucuronidase, an enzyme that may play a role in increasing the amount of carcinogens in the colon.
- New Cell Research Confirms Wild Blueberry Antioxidant Power
New research published in the current issue of the Journal of Agricultural and Food Chemistry (55 (22), 8896-8907, 2007) shows that Wild Blueberries have the highest cellular antioxidant activity of selected fruits tested.
- New Cell Research Confirms Wild Blueberry Antioxidant Power
New research published in the current issue of the Journal of Agricultural and Food Chemistry (55 (22), 8896-8907, 2007) shows that Wild Blueberries have the highest cellular antioxidant activity of selected fruits tested.
- New Cell Research Confirms Wild Blueberry Antioxidant Power
New research published in the current issue of the Journal of Agricultural and Food Chemistry (55 (22), 8896-8907, 2007) shows that Wild Blueberries have the highest cellular antioxidant activity of selected fruits tested.
- New Cell Research Confirms Wild Blueberry Antioxidant Power
New research published in the current issue of the Journal of Agricultural and Food Chemistry (55 (22), 8896-8907, 2007) shows that Wild Blueberries have the highest cellular antioxidant activity of selected fruits tested.
- Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients: A Promising Intervention Study
Immunotec Inc. has announced the successful completion of a multi-center randomized, double-blind clinical trial on cancer-related weight loss (cachexia) in lung cancer patients, concluding that patients treated with IMN 1207, a research formulation of the undenatured whey protein Immunocal(R)/HMS 90(R), a dietary natural health supplement and precursor to glutathione, showed significant increases in body weight (Tozer et al. Antioxidants & Redox Signaling (2008) 10:395-402).
- Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients: A Promising Intervention Study
Immunotec Inc. has announced the successful completion of a multi-center randomized, double-blind clinical trial on cancer-related weight loss (cachexia) in lung cancer patients, concluding that patients treated with IMN 1207, a research formulation of the undenatured whey protein Immunocal(R)/HMS 90(R), a dietary natural health supplement and precursor to glutathione, showed significant increases in body weight (Tozer et al. Antioxidants & Redox Signaling (2008) 10:395-402).
- Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients: A Promising Intervention Study
Immunotec Inc. has announced the successful completion of a multi-center randomized, double-blind clinical trial on cancer-related weight loss (cachexia) in lung cancer patients, concluding that patients treated with IMN 1207, a research formulation of the undenatured whey protein Immunocal(R)/HMS 90(R), a dietary natural health supplement and precursor to glutathione, showed significant increases in body weight (Tozer et al. Antioxidants & Redox Signaling (2008) 10:395-402).
- Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients: A Promising Intervention Study
Immunotec Inc. has announced the successful completion of a multi-center randomized, double-blind clinical trial on cancer-related weight loss (cachexia) in lung cancer patients, concluding that patients treated with IMN 1207, a research formulation of the undenatured whey protein Immunocal(R)/HMS 90(R), a dietary natural health supplement and precursor to glutathione, showed significant increases in body weight (Tozer et al. Antioxidants & Redox Signaling (2008) 10:395-402).
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Ginseng, one of the most widely used herbs in traditional Chinese medicine, may improve survival and quality of life after a diagnosis of breast cancer, according to a recent study by Vanderbilt-Ingram Cancer Center researchers. The large epidemiological study, led by Xiao-Ou Shu, M.D., Ph.D., was published online recently in the American Journal of Epidemiology.
Ginseng is a slow-growing perennial herb whose roots have been used in traditional Chinese medicine for more than 2,000 years. The two main classes of ginseng – red and white – have different biological effects, according to traditional Chinese medicine theory. White, or unprocessed, ginseng is used over long periods to promote general health, vitality and longevity. Red, or processed, ginseng provides a much stronger effect and is used for short periods to aid in disease recovery.
Both varieties of ginseng contain more than 30 chemicals, called ginsenosides, which have anti-tumor effects in cell culture and animal studies, suggesting that the herbs may provide specific benefits to cancer patients. In fact, ginseng use has been increasing among cancer patients in recent years, particularly in women diagnosed with breast cancer.
However, despite the encouraging laboratory findings, scientific analysis of ginseng's health benefits in patient populations has been lacking. "There is a lot of skepticism about herbal medicine," said Shu. "That is why we are taking the observational approach at this time to see whether there is any efficacy. If so, we can go to the next phase. … and eventually go to clinical trials."
Shu and colleagues assessed the effects of ginseng use in breast cancer survivors as part of a large epidemiological study, the Shanghai Breast Cancer Study, which has followed 1,455 breast cancer patients in Shanghai since 1996. For the current study, Shu and colleagues evaluated breast cancer patients for ginseng use both before and after their diagnosis of breast cancer. All patients who used ginseng had received at least one type of conventional cancer therapy (e.g., surgery, chemotherapy and/or radiotherapy). Information on ginseng use prior to cancer diagnosis, which was available for every subject, was used to determine whether prior ginseng use predicted survival. At follow up – about three to four years after diagnosis – the researchers asked about ginseng use since diagnosis. That information, which was available only for survivors, was used to look at quality of life measurements – i.e., physical, psychological, social and material well-being.
Before diagnosis, about a quarter of patients (27.4 percent) reported using ginseng regularly. After diagnosis, that percentage jumped to 62.8 percent, the researchers found. They also found significant improvements in both survival and quality of life measures in patients who used ginseng. "When patients used ginseng prior to diagnosis, they tended to have higher survival," Shu explained. "Ginseng use after cancer diagnosis was related to improved quality of life."
The findings suggest that ginseng may provide tangible benefits to breast cancer survivors, but there are limitations to the study. The varieties and the methods of ginseng use and the use of other complementary and alternative therapies could not be fully accounted for in the analysis. Also, the quality of life measures exclusively relied on patient self-reporting.
Although side effects of ginseng use were not recorded in this study, Shu warned that the seemingly innocuous root can create problems when improperly used and should be taken with caution. "It's not a 'drug' in terms of being managed by the FDA, but it was used as a drug in traditional Chinese medicine," she said. "Any drug may have some side effects and may interact with other drugs. So, discuss with your primary care doctor before you decide to take ginseng roots or products."
Shu hopes to confirm and expand the current findings through continued collection of data in this patient population, from another ongoing study of 4,000 breast cancer patients, and eventually, in randomized clinical trials. Scientific study of complementary and alternative medicines is tricky though, said Shu. "Chinese traditional medicine is very individualized. It gives you different drugs based on your symptoms and your overall health. There is much to be learnt." |